Breaking News

CordenPharma Expands Highly Potent API Capabilities

Completes process bay for category 4 compounds

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

CordenPharma has completed a new highly potent API process bay for category 4 compounds. This new investment comes after the completion in early 2016 of a new CTD2 facility for the handling (development/manufacturing) of oral solid dosage drug product manufacturing of highly potent and oncology compounds in its CordenPharma Plankstadt (Germany) facility, along with further expansion of capabilities in handling sterile oncology drug products at CordenPharma Latina (Italy). The new API process ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters